Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aidong Qi

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Bioorganic & Medicinal Chemistry Letters|November 28, 2021
Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M<sub>4</sub> muscarinic acetylcholine receptorAaron M Bender, Trever R Carter, Matthew Spock, et al.
Journal of Medicinal Chemistry|February 5, 2026
Drug Repurposing: Conversion of the Peripherally Restricted HIV Protease Inhibitor Amprenavir to Potent, Selective, and CNS-Penetrant Agonists for the Cannabinoid Receptor 2Daniel H Haymer, Renn A Duncan, Alice L Rodriguez, et al.
ACS Medicinal Chemistry Letters|August 20, 2021
Discovery of VU6028418: A Highly Selective and Orally Bioavailable M<sub>4</sub> Muscarinic Acetylcholine Receptor AntagonistMatthew Spock, Trever R Carter, Katrina A Bollinger, et al.
ACS Pharmacology & Translational Science|August 23, 2021
Discovery of the First Selective M<sub>4</sub> Muscarinic Acetylcholine Receptor Antagonists with <i>in Vivo</i> Antiparkinsonian and Antidystonic EfficacyMark S Moehle, Aaron M Bender, Jonathan W Dickerson, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Bioorganic & Medicinal Chemistry Letters|November 28, 2021
Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M<sub>4</sub> muscarinic acetylcholine receptorAaron M Bender, Trever R Carter, Matthew Spock, et al.
Journal of Medicinal Chemistry|February 5, 2026
Drug Repurposing: Conversion of the Peripherally Restricted HIV Protease Inhibitor Amprenavir to Potent, Selective, and CNS-Penetrant Agonists for the Cannabinoid Receptor 2Daniel H Haymer, Renn A Duncan, Alice L Rodriguez, et al.
ACS Medicinal Chemistry Letters|August 20, 2021
Discovery of VU6028418: A Highly Selective and Orally Bioavailable M<sub>4</sub> Muscarinic Acetylcholine Receptor AntagonistMatthew Spock, Trever R Carter, Katrina A Bollinger, et al.
ACS Pharmacology & Translational Science|August 23, 2021
Discovery of the First Selective M<sub>4</sub> Muscarinic Acetylcholine Receptor Antagonists with <i>in Vivo</i> Antiparkinsonian and Antidystonic EfficacyMark S Moehle, Aaron M Bender, Jonathan W Dickerson, et al.
Pageof 2